COVID-19 CONVALESCENT PLASMA for lung diseases, interstitial

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Apr 2020: Trial registered, NCT04333251
  2. 17 Apr 2020: Trial started, NCT04333251
  3. 26 Jan 2026: Trial withdrawn, NCT04333251

The trials

NCT04333251: Study Testing Convalescent Plasma vs Best Supportive Care

State
Withdrawn before it started
Phase
Phase 1
People
0 taking part
Started
17 Apr 2020
Primary completion
7 Sep 2021
Arms
convalescent plasma
Results
None posted
  1. 3 Apr 2020: Trial registered
  2. 17 Apr 2020: Trial started
  3. 26 Jan 2026: Trial withdrawn

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Also known as COVID-19 Convalescent Plasma (CCP), High-titer Convalescent COVID-19 Plasma (CCP1), Transfusion of SARS-CoV-2 Convalescent Plasma., anti-SARS-CoV-2 convalescent plasma, anti-SARS-CoV-2 plasma, high-titer anti-Sars-CoV-2 plasma.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.